Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

Market Cap	22.61B
Revenue (ttm)	4.74B
Net Income (ttm)	935.80M
Shares Out	2.23B
EPS (ttm)	0.42
PE Ratio	24.27
Forward PE	26.45
Dividend	0.27 (2.66%)
Ex-Dividend Date	Jun 10, 2025

Volume	4,553,443
Average Volume	8,561,066
Open	10.14
Previous Close	10.14
Day's Range	10.12 - 10.18
52-Week Range	9.71 - 14.74
Beta	0.10
RSI	44.08
Earnings Date	Mar 31, 2026

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; urso...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,184
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301301

Financial Performance

In 2024, SHE:301301's revenue was 5.76 billion, an increase of 19.38% compared to the previous year's 4.82 billion. Earnings were 1.40 billion, an increase of 48.88%.